Study on HMPL-A580 for Adults with Advanced or Metastatic Solid Tumors
Sponsor: Hutchmed
ClinicalTrials ID:NCT07396584
This clinical trial is testing a new drug, HMPL-A580, to see if it is safe and effective for treating adults with advanced or metastatic solid tumors that cannot be surgically removed.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
This study is the first time HMPL-A580 is being tested in humans. It involves multiple centers and is open to participants with advanced or metastatic solid tumors that cannot be removed by surgery. The main goals are to find out how safe and tolerable the drug is, and to determine the best dose to use in future studies.
Description
The purpose of this study is to evaluate the safety and tolerability of HMPL-A580 in patients with solid tumors that are advanced or have spread to other parts of the body. Researchers aim to find the maximum dose that can be given safely and to identify the best dose for future phases of the study. The study will also look at how well the drug works at these doses in treating selected solid tumors.
Eligibility Criteria
Inclusion Criteria
- Understand the study and agree to sign an informed consent form.
- Be 18 years or older.
- Have a confirmed diagnosis of an advanced or metastatic solid tumor that cannot be surgically removed.
- Have at least one tumor that can be measured using standard criteria.
- Have a life expectancy of at least 12 weeks.
- Be in good overall health with an ECOG performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
Exclusion Criteria
- Have type 1 diabetes or uncontrolled type 2 diabetes.
- Are using certain medications that affect how the body processes drugs, within a specified time before starting the study.
- Have had major surgery within 28 days before starting the study.
- Have an active infection that requires treatment.
- Have received a live vaccine within 3 months before joining the study.
- Have a history of inflammatory bowel diseases.
- Are allergic to any component of HMPL-A580.
- Are pregnant or breastfeeding.
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| University of California Irvine Medical Center | 92868 | Orange | California |
| BRCR Global | 33324 | Plantation | Florida |
| Florida Clinical Trials Group LLC (Plantation) | 33324 | Plantation | Florida |
| Florida Clinical Trials Group LLC (Tamarac) | 33319 | Tamarac | Florida |
| University of Washington/Fred Hutchinson Cancer Center | 98109 | Seattle | Washington |
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.